Veltuzumab

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.